↓ Skip to main content

TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, November 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (62nd percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter
1 X user
patent
2 patents

Citations

dimensions_citation
55 Dimensions

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas
Published in
Journal of Experimental & Clinical Cancer Research, November 2017
DOI 10.1186/s13046-017-0619-9
Pubmed ID
Authors

Ming-Zhi Han, Ran Xu, Yang-Yang Xu, Xin Zhang, Shi-Lei Ni, Bin Huang, An-Jing Chen, Yu-Zhen Wei, Shuai Wang, Wen-Jie Li, Qing Zhang, Gang Li, Xin-Gang Li, Jian Wang

Abstract

Transgelin-2 (TAGLN2) is a member of the calponin family of actin-bundling proteins that is involved in the regulation of cell morphology, motility, and cell transformation. Here, the clinical significance and potential function of TAGLN2 in malignant gliomas were investigated. Molecular and clinical data was obtained from The Cancer Genome Atlas (TCGA) database. Gene ontology and pathway analysis was used to predict potential functions of TAGLN2. RNA knockdown was performed using siRNA or lentiviral contructs in U87MG and U251 glioma cell lines. Cells were characterized in vitro or implanted in vivo to generate orthotopic xenografts in order to assess molecular status, cell proliferation/survival, and invasion by Western blotting, flow cytometry, and 3D tumor spheroid invasion assay, respectively. Increased TAGLN2 expression was associated with increasing tumor grade (P < 0.001), the mesenchymal molecular glioma subtype and worse prognosis in patients (P < 0.001). Immunohistochemistry performed with anti-TAGLN2 on an independent cohort of patients (n = 46) confirmed these results. Gene silencing of TAGLN2 in U87MG and U251 significantly inhibited invasion and tumor growth in vitro and in vivo. Western blot analysis revealed that epithelial-mesenchymal transition (EMT) molecular markers, such as N-cadherin, E-cadherin, and Snail, were regulated in a manner corresponding to suppression of the EMT phenotype in knockdown experiments. Finally, TAGLN2 was induced ~ 2 to 3-fold in U87MG and U251 cells by TGFβ2, which was also elevated in GBM and highly correlated with TAGLN2 mRNA levels (P < 0.001). Our findings indicate that TAGLN2 exerts a role in promoting the development of human glioma. The regulation and function of TAGLN2 therefore renders it as a candidate molecular target for the treatment of GBM.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 17%
Student > Ph. D. Student 6 15%
Student > Bachelor 3 7%
Student > Master 3 7%
Student > Postgraduate 2 5%
Other 5 12%
Unknown 15 37%
Readers by discipline Count As %
Neuroscience 8 20%
Biochemistry, Genetics and Molecular Biology 5 12%
Agricultural and Biological Sciences 4 10%
Medicine and Dentistry 4 10%
Nursing and Health Professions 1 2%
Other 4 10%
Unknown 15 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 October 2019.
All research outputs
#8,264,793
of 25,382,440 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#535
of 2,380 outputs
Outputs of similar age
#127,334
of 342,377 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#7
of 39 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 2,380 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,377 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.